{
  "abstract": "In their manuscript, Jeong et al investigated the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4is), in a rotenone-based mouse model of Parkinson’s disease (PD).1 The study explored the association between diabetes and PD, focusing on the potential therapeutic benefits of glucagon-like peptide-1 receptor (GLP-1-R) agonists,2 given that DPP-4is are hypoglycaemic agents that enhance the bioavailability of GLP-1.3 However, the precise molecular mechanisms underlying the potential neuroprotective effects of DPP-4is remain unclear, which this study aimed to elucidate.",
  "authors": [
    {
      "affiliations": [
        "Center for Translational Medicine, St Anne’s University Hospital Brno, Brno, South Moravian Region, Czech Republic",
        "Department of Physiology, Faculty of Medicine, Masaryk University, Brno, South Moravian Region, Czech Republic"
      ],
      "name": "Amit Khairnar"
    },
    {
      "affiliations": [
        "Applied Neuroscience Research Group, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic",
        "First Department of Neurology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic"
      ],
      "name": "Irena Rektorova"
    },
    {
      "affiliations": [
        "Department of Experimental Neurodegeneration, University Medical Center Göttingen Center for Biostructural Imaging of Neurodegeneration, Göttingen, NDS, Germany",
        "Translational and Clinical Research Institute, Faculty of Medical Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, UK"
      ],
      "name": "Tiago F Outeiro"
    }
  ],
  "title": "“DPP- 4 inhibitor alleviates gut-brain axis Parkinson’s disease pathology” - can dipeptidyl peptidase 4 inhibitors be repurposed as disease-modifying drugs for body-first Parkinson’s disease patients?",
  "uid": "b3ff0338-8e41-5856-a068-caec5a0d6876"
}